Sonrotoclax
SimSon publishes no observed catalogue coverage for Sonrotoclax while an FDA novel drug approval dated 13 May 2026 is already in force — a near-term BUILD opportunity.Source
- GAP
- A commercially relevant molecule or product appears absent from SimSon while demand or catalyst evidence exists.
- Here: SimSon coverage is no-listing-observed across every applicable probe, and a dated catalyst exists.
- TIMING
- A dated catalyst is forcing analytical work now — a novel approval, an NDSRI limit, a loss of exclusivity or a generic filing wave.
- Here: A dated catalyst scores 84.7/100 and SimSon holds no observed coverage yet.
Make something SimSon does not currently list.
Scope a new sonrotoclax product family — no listing was observed at SimSon or at any checked supplier.
First step: Scientific feasibility review of the absent compounds, then confirm the absence at supplier level.
Review the absence evidence- Urgency
- Act now
- The catalyst is already in force — it dates from 2026-05-13, 4 months ago.
- Owner
- Not set
- Owner is not set: the system has no access to SimSon's org chart and will not guess one.
- Value — not public
- Cannot be established
- Revenue and margin are not public. This ranks the strength of the public signal, not the size of the prize — see what internal data would settle it.
Why now
Why SimSon
This is an observed absence, not a failed search: every applicable probe completed against an identity-grade query before the verdict was recorded.
No listing was observed on SimSon's own catalogue for sonrotoclax after every applicable probe completed against an identity-grade query. This is an observed absence, not a failed search.Source
Organisations publicly associated with this molecule
No public filing record names an organisation for sonrotoclax in the current evidence set, so no buyer-candidate is asserted.
How this decision was reached
R1_GAP_TIMINGSimSon has no observed listing for this molecule, every applicable probe completed, and a dated catalyst is already in force.
No listing was observed at SimSon across every applicable probe, and the catalyst scores 84.7/100.
This is a system recommendation, not system evidence. It was selected by a fixed rule evaluated top to bottom over the values above — no model, no judgement. Change the inputs and the rule changes with them.
BUILD — rule R1_GAP_TIMING. No listing was observed at SimSon across every applicable probe, and the catalyst scores 84.7/100.
Opportunity score
- Market activity
- 13.3
- Regulatory catalyst
- 84.7
- Competitor scarcity
- Not scored
- Capability adjacency
- 0.0
- Evidence quality
- 71.8
Why competitor scarcity is not scored
Identity-grade competitor coverage was insufficient across the three suppliers this dimension requires. The 20 weight points it would have carried were removed from the denominator rather than scored as zero, so the remaining dimensions keep their relative influence.
A false competitive gap is materially worse than a missing scarcity score, so the dimension stays unscored until the evidence standard is met.
- Distinct ANDA sponsors
- 0
- Marketed products
- 4
- Distinct trial sponsors
- Not checked
ClinicalTrials.gov disallows our agent on /api/ in its robots.txt. The trial component was omitted from the weighted average rather than scored zero, and no substitute source was used.
Evidence ledger
- Retrieval datePrimaryLive retrievalU.S. Food and Drug AdministrationFDA Orange Book data filesobserved
Orange Book patent row
N 220711 product 002
https://www.fda.gov/media/76860/download?attachmentRetrieved 13 SEPT 2026
- Retrieval datePrimaryLive retrievalSimSon Pharma LimitedSimSon public catalogueobserved
SimSon catalogue coverage — sonrotoclax
0 products observed on https://www.simsonpharma.com/products/sonrotoclax
https://www.simsonpharma.com/products/sonrotoclaxRetrieved 13 SEPT 2026
- Publisher datePrimaryLive retrievalU.S. Food and Drug AdministrationFDA novel drug approvals 2026observed
sonrotoclax
sonrotoclax; approved 2026-05-13; To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026Retrieved 13 SEPT 2026
What internal SimSon data would change this decision?
Everything above was built from information anyone can retrieve. The scoring is deterministic and the evidence is cited — but each of the following would sharpen this recommendation materially, and none of it is public.
Realised selling price and margin per catalogue item
Every opportunity here is ranked by signal strength, never by profit. A high-scoring molecule may be one SimSon sells at its thinnest margin.
Would be resolved by: SimSon price book and cost model
Synthesis feasibility and past success rate
Capability adjacency measures what SimSon has published, not what it can make. A BUILD recommendation is a question for the bench, not an instruction.
Would be resolved by: SimSon project history and R&D records
Actual competitor pricing, stock and terms
Public catalogues show listings, never terms. Even where a competitor listing is observed, it says nothing about price or availability.
Would be resolved by: Not public — sales intelligence or direct enquiry
competitor scarcity is NOT SCORED (0 of the 3 required suppliers hold an identity-grade verdict); the ClinicalTrials.gov trial-sponsor component is omitted from market activity because that publisher's robots.txt disallows our agent on /api/ — omitted, not scored zero.Source